BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – Should You Sell?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $8.43, but opened at $7.77. BioCryst Pharmaceuticals shares last traded at $7.15, with a volume of 1,709,944 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have issued reports on BCRX shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Stock Down 4.0 %

The firm has a 50 day moving average of $7.82 and a 200-day moving average of $6.97. The firm has a market capitalization of $1.46 billion, a P/E ratio of -11.57 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.19) earnings per share. As a group, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. Series C lifted its stake in shares of BioCryst Pharmaceuticals by 62.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after acquiring an additional 3,140,804 shares during the last quarter. Kynam Capital Management LP raised its position in BioCryst Pharmaceuticals by 41.9% in the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after purchasing an additional 1,927,491 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of BioCryst Pharmaceuticals by 528.0% during the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock valued at $6,874,000 after purchasing an additional 935,132 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Finally, Point72 Europe London LLP bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $1,654,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.